ImmunityBio Management

Management criteria checks 4/4

ImmunityBio's CEO is Rich Adcock, appointed in Oct 2020, has a tenure of 3.58 years. total yearly compensation is $4.01M, comprised of 19.7% salary and 80.3% bonuses, including company stock and options. directly owns 0.036% of the company’s shares, worth $1.94M. The average tenure of the management team and the board of directors is 3.6 years and 3.8 years respectively.

Key information

Rich Adcock

Chief executive officer

US$4.0m

Total compensation

CEO salary percentage	19.7%
CEO tenure	3.6yrs
CEO ownership	0.04%
Management average tenure	3.6yrs
Board average tenure	3.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Rich Adcock's remuneration changed compared to ImmunityBio's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$583m
Sep 30 2023	n/a	n/a	-US$458m
Jun 30 2023	n/a	n/a	-US$473m
Mar 31 2023	n/a	n/a	-US$430m
Dec 31 2022	US$4m	US$791k	-US$417m
Sep 30 2022	n/a	n/a	-US$400m
Jun 30 2022	n/a	n/a	-US$376m
Mar 31 2022	n/a	n/a	-US$370m
Dec 31 2021	US$29m	US$765k	-US$347m
Sep 30 2021	n/a	n/a	-US$323m
Jun 30 2021	n/a	n/a	-US$301m
Mar 31 2021	n/a	n/a	-US$264m
Dec 31 2020	US$843k	US$141k	-US$222m

Compensation vs Market: Rich's total compensation ($USD4.01M) is below average for companies of similar size in the US market ($USD8.39M).

Compensation vs Earnings: Rich's compensation has been consistent with company performance over the past year.

CEO

Rich Adcock (54 yo)

3.6yrs

Tenure

US$4,008,507

Compensation

Mr. Richard Gerald Adcock, also known as Rich, has been the President of ImmunityBio, Inc. since March 05, 2021 and serves as its Director since March 29, 2021. He has been the Chief Executive Officer of I...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Patrick Soon-Shiong	Executive Chairman of the Board	9.5yrs	US$3.79m	43.01% $ 2.3b
Richard Adcock	President	3.6yrs	US$4.01m	0.036% $ 1.9m
David Sachs	CFO, Principal Financial Officer & Principal Accounting Officer	4.8yrs	US$1.66m	0.027% $ 1.5m
Barry Simon	Chief Corporate Affairs Officer & Director	3.2yrs	no data	0.46% $ 25.0m
Leonard Sender	Chief Operating Officer	4.2yrs	no data	no data
Enrique Diloné	Chief Technology Officer	1.3yrs	no data	no data
Jason Liljestrom	General Counsel & Corporate Secretary	2.9yrs	no data	no data
Sarah Singleton	Chief Communications Officer & Head of Patient Advocacy	4.2yrs	no data	no data
Sandeep Reddy	Chief Medical Officer	3.8yrs	no data	no data
Hans Klingemann	Chief Science Officer of Cellular	no data	no data	no data
Regan Lauer	Chief Accounting Officer	2.5yrs	no data	0.014% $ 753.5k
Elizabeth Gabitzsch	Senior Vice President of Product Development & Vaccine Programs	less than a year	no data	no data

3.6yrs

Average Tenure

55yo

Average Age

Experienced Management: IBRX's management team is considered experienced (3.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Patrick Soon-Shiong	Executive Chairman of the Board	9.5yrs	US$3.79m	43.01% $ 2.3b
Richard Adcock	President	3.2yrs	US$4.01m	0.036% $ 1.9m
Barry Simon	Chief Corporate Affairs Officer & Director	17.3yrs	no data	0.46% $ 25.0m
Christobel Selecky	Independent Director	3.8yrs	US$469.26k	0% $ 0
Wesley Clark	Independent Director	3.3yrs	US$465.00k	0.0012% $ 63.8k
Michael Blaszyk	Independent Director	8.8yrs	US$509.26k	0.039% $ 2.1m
John Brennan	Independent Director	3.3yrs	US$472.50k	0.0037% $ 199.6k
Cheryl Cohen	Lead Independent Director	4.9yrs	US$482.50k	0.030% $ 1.6m
Linda Maxwell	Independent Director	3.2yrs	US$486.00k	0% $ 0

3.8yrs

Average Tenure

67yo

Average Age

Experienced Board: IBRX's board of directors are considered experienced (3.8 years average tenure).

ImmunityBio Management

Management criteria checks 4/4

Key information

Recent management updates

ImmunityBio, Inc., Annual General Meeting, Jun 11, 2024

Insufficient new directors

ImmunityBio, Inc. Appoints Enrique Diloné as Chief Technology Officer, Effective August 14, 2023

Independent Director recently bought US$71k worth of stock

ImmunityBio, Inc., Annual General Meeting, Jun 13, 2023

President exercised options and sold US$183k worth of stock

Recent updates

Consensus revenue estimates increase by 639%, EPS downgraded

ImmunityBio, Inc., Annual General Meeting, Jun 11, 2024

ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer

ImmunityBio, Inc. Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

ImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer Battle

Insufficient new directors

Consensus revenue estimates increase by 25%

No longer forecast to breakeven

New minor risk - Profitability

New major risk - Financial position

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ImmunityBio Announces Data from A Phase 1 Pilot Study

ImmunityBio: Financial And Regulatory Risks Outweigh Anktiva's Promise

New major risk - Share price stability

ImmunityBio, Inc. Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

Forecast to breakeven in 2026

ImmunityBio: Buy Low Now Vs. Buy High Later

Immunitybio, Inc. Announces Findings from Patient-Reported Outcomes (PROs) of Participants in the Phase 2/3 Quilt 3.032 Study of N-803 Plus BCG

Consensus revenue estimates decrease by 54%, EPS upgraded

New major risk - Financial position

ImmunityBio, Inc. Announces First Data for Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-Tumor Activity

ImmunityBio, Inc. Announces U.S. Food and Drug Administration Accepts its BLA Resubmission as Complete and Sets New PDUFA Date

New major risk - Share price stability

ImmunityBio, Inc. Announces Biological License Application Resubmission for N-803 in BCG Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ

New major risk - Shareholder dilution

ImmunityBio, Inc. announced that it has received $200 million in funding from Nant Capital, LLC

ImmunityBio, Inc. announced that it has received $200 million in funding from Nant Capital, LLC

Consensus revenue estimates increase by 20%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Jakubowitz Law Reminds Immunitybio Shareholders of A Lead Plaintiff Deadline of August 29, 2023

ImmunityBio, Inc. Appoints Enrique Diloné as Chief Technology Officer, Effective August 14, 2023

ImmunityBio, Inc. Announces Findings from a Phase 1 Study Showing Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells

Pomerantz Law Firm Announces the Filing of a Class Action Against ImmunityBio, Inc. and Certain Officers – IBRX

Independent Director recently bought US$71k worth of stock

ImmunityBio, Inc., Annual General Meeting, Jun 13, 2023

ImmunityBio, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration Regarding Its Biologics License Application

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

President exercised options and sold US$183k worth of stock

ImmunityBio, Inc. announced that it expects to receive $50 million in funding

Price target decreased to US$9.00

High number of new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

ImmunityBio: PDUFA Pending

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.23 loss in 2Q 2021)

ImmunityBio: Compelling Data In Bladder Cancer, Yet Funding Issues Remain

Consensus forecasts updated

ImmunityBio, Inc. Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma in Situ

ImmunityBio, Inc. Announces Quilt Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer

ImmunityBio: Ready To Shift Gears After Long-Awaited BLA Submission

ImmunityBio, Inc. Submits Biologics License Application for N-803 Plus Bcg for Patients with Bcg-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

First quarter 2022 earnings: EPS and revenues miss analyst expectations

ImmunityBio, Inc., Annual General Meeting, Jun 14, 2022

Price target decreased to US$20.00

High number of new directors

Immunitybio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer

ImmunityBio: Extensive Pipeline, NDA Expected For Anktiva This Quarter

ImmunityBio, Inc. Announces Study Results That Further Demonstrate the Potential for Use of Memory-Like Cytokine-Enriched Natural Killer (m-ceNK) Cells for the Treatment of Cancer

ImmunityBio, Inc. Announces Study Results That Further Demonstrate the Potential for Use of Memory-Like Cytokine-Enriched Natural Killer (m-ceNK) Cells for the Treatment of Cancer

ImmunityBio, Inc. (NasdaqGS:IBRX) completed the acquisition of Dunkirk Manufacturing Facility and Certain Related Assets of Athenex, Inc. (NasdaqGS:ATNX).

ImmunityBio, Inc. Announces Positive Data from its Late-Stage Bladder Cancer Trial

President exercised options and sold US$159k worth of stock

ImmunityBio, Inc. Announces Promising Clinical Study Results for Kick and Kill HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy

ImmunityBio, Inc. Announces Interim Results in its Metastatic Pancreatic Cancer Trial

ImmunityBio: Company Leaves 2021 On A High-Note; Share Price Still Falls Flat

ImmunityBio, Inc. Announces Updates on Its Clinical Year-End Review of Strategic Milestones

Third quarter 2021 earnings released: US$0.22 loss per share (vs US$0.17 loss in 3Q 2020)

ImmunityBio: Demoralization Of The Bulls By Deflating The Share Price

ImmunityBio, Inc. Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with A Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-Free in Phase 2/3 Trial